This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Study to Evaluate the Safety and Efficacy of CCX168 in Subjects With ANCA-Associated Vasculitis

This study has been completed.
Information provided by (Responsible Party):
ChemoCentryx Identifier:
First received: May 26, 2011
Last updated: July 25, 2016
Last verified: July 2016
The aim of this trial is to optimize the treatment to induce remission for patients with non-life-threatening anti-neutrophil cytoplasmic antibody vasculitis (AAV). The intent is to reduce the toxicity of induction therapy by reducing the overall exposure to or eliminating entirely the use of systemic corticosteroids during the induction period with an inhibitor of the complement C5a receptor plus cyclophosphamide or rituximab.

Condition Intervention Phase
Vasculitis Drug: Placebo Drug: CCX168 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of CCX168 in Subjects With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis on Background of Cyclophosphamide or Rituximab Treatment

Resource links provided by NLM:

Further study details as provided by ChemoCentryx:

Primary Outcome Measures:
  • Safety of CCX168 in subjects with AAV [ Time Frame: 169 days ]
    Safety assessments include adverse events, physical examination abnormalities, vital signs and clinical laboratory tests (including blood chemistry, hematology and urinalysis).

  • Efficacy of CCX168 in subjects with AAV [ Time Frame: 169 days ]
    Efficacy will be assessed by BVAS (a global disease activity index).

Secondary Outcome Measures:
  • Systemic corticosteroid use [ Time Frame: 169 days ]
    Systemic corticosteroid use based on total oral corticosteroid dose and duration of oral corticosteroid use

Enrollment: 67
Study Start Date: August 2011
Study Completion Date: January 2016
Primary Completion Date: October 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Placebo Drug: Placebo
BID for 84 days
Experimental: CCX168
Active study medication
Drug: CCX168
BID for 84 days

Detailed Description:

The primary safety objective of this study is to evaluate the safety and tolerability of CCX168 in subjects with AAV on background cyclophosphamide or rituximab treatment.

The primary efficacy objective is to evaluate the efficacy of CCX168 based on the Birmingham Vasculitis Activity Score (BVAS) version 3.

The secondary objectives of this study include assessment of the feasibility of reducing or eliminating the use of corticosteroids in the treatment of subjects with ANCA-associated vasculitis without the need for rescue corticosteroid measures and the effect of CCX168 on several disease parameters.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Key Inclusion Criteria:

  • Clinical diagnosis of granulomatosis with polyangiitis (Wegener's), microscopic polyangiitis or renal limited vasculitis
  • Male and postmenopausal or surgically sterile female subjects aged at least 18 years with new or relapsed AAV where treatment with cyclophosphamide or rituximab would be required
  • Positive indirect immunofluorescence (IIF) test for P-ANCA or C-ANCA, or positive ELISA test for anti-proteinase-3 (PR3) or anti-myeloperoxidase (MPO) at screening
  • Estimated glomerular filtration rate (eGFR) ≥ 20mL/min
  • Have at least one "major" item, or at least 3 non-major items, or at least 2 renal items on the BVAS version 3

Key Exclusion Criteria:

  • Severe disease as determined by rapidly progressive glomerulonephritis, alveolar hemorrhage, hemoptysis, rapid-onset mononeuritis multiplex or central nervous system involvement
  • Any other multi-system autoimmune disease
  • Medical history of coagulopathy or bleeding disorder
  • Received cyclophosphamide within 12 weeks of screening; if on azathioprine, mycophenolate mofetil or methotrexate at the time of screening, these drugs must be withdrawn prior to receiving the cyclophosphamide or rituximab dose on Day 1
  • Received high-dose intravenous corticosteroids within 4 weeks of screening
  • On an oral dose of a corticosteroid of more than 10mg prednisone-equivalent at the time of screening
  • Received rituximab or other B-cell antibody within 52 weeks of screening or 26 weeks provided B cell reconstitution has occurred; received anti-TNF treatment, abatacept, alemtuzumab, IVIg or plasma exchange within 12 weeks of screening
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01363388

  Show 44 Study Locations
Sponsors and Collaborators
Study Director: Pirow Bekker, MD, PhD ChemoCentryx Inc
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: ChemoCentryx Identifier: NCT01363388     History of Changes
Other Study ID Numbers: CL002_168
Study First Received: May 26, 2011
Last Updated: July 25, 2016

Additional relevant MeSH terms:
Vascular Diseases
Cardiovascular Diseases
Antibodies, Antineutrophil Cytoplasmic
Immunologic Factors
Physiological Effects of Drugs processed this record on September 19, 2017